Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient Perspectives on Electronic Communication of Cancer Diagnoses.

JAMA network open·2026
Same author

Predictive Biomarkers for Immune Checkpoint Inhibitor Efficacy: Challenges, Innovations, and a Pathway to Precision Medicine in the Era of Cancer Immunotherapy.

Clinical chemistry·2026
Same author

Deciphering small sequence differences in T cell receptor-antigen pairing.

Nature communications·2026
Same author

A first-in-human, open-label multicentre Phase 1 study of the orally administered E7386 in patients with selected advanced neoplasms.

British journal of cancer·2026
Same author

Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial.

JAMA·2026
Same journal

Ivonescimab: The Next United States Food and Drug Administration Project Optimus Flashpoint?

JTO clinical and research reports·2026
Same journal

Clinical Outcomes for Patients who Received Both Trastuzumab Deruxtecan (T-DXd) and Trastuzumab Emtansine (T-DM1) for HER2-Mutant non-Small Cell Lung Cancer.

JTO clinical and research reports·2026
Same journal

Trastuzumab Deruxtecan Induces Complete Pathological Response in Oligometastatic HER2-Mutant NSCLC: Case Report.

JTO clinical and research reports·2026
Same journal

Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, <i>EGFR</i> Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial.

JTO clinical and research reports·2026
Same journal

Differential Treatment Effects by Smoking Status for NSCLC Therapies (2010-2023): A Meta-Analysis.

JTO clinical and research reports·2026
Same journal

Lung Adenocarcinoma Developing Pleomorphic Carcinoma With <i>ERBB3</i> Amplification After Acquired Resistance to Sotorasib: A Case Report.

JTO clinical and research reports·2026
See all related articles

Related Experiment Video

Updated: Jun 6, 2025

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

6.0K

Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer.

Mitchell S von Itzstein1,2, Jialiang Liu3, Hong Mu-Mosley2

  • 1Department of Internal Medicine (Division of Hematology-Oncology), University of Texas Southwestern Medical Center, Dallas, Texas.

JTO Clinical and Research Reports
|December 2, 2024
PubMed
Summary
This summary is machine-generated.

Black lung cancer patients show distinct immune profiles compared to White patients, with higher levels of certain inflammatory cytokines and immune cells. Further research is needed to understand the clinical impact of these differences.

Keywords:
CytokinesDisparitiesImmune cellsImmunotherapyLung cancerRace

More Related Videos

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

381
Flow Cytometric Analysis for Identification of the Innate and Adaptive Immune Cells of Murine Lung
09:57

Flow Cytometric Analysis for Identification of the Innate and Adaptive Immune Cells of Murine Lung

Published on: November 16, 2021

6.5K

Related Experiment Videos

Last Updated: Jun 6, 2025

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation
08:44

Identification and Characterization of Immunogenic RNA Species in HDM Allergens that Modulate Eosinophilic Lung Inflammation

Published on: May 30, 2020

6.0K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

381
Flow Cytometric Analysis for Identification of the Innate and Adaptive Immune Cells of Murine Lung
09:57

Flow Cytometric Analysis for Identification of the Innate and Adaptive Immune Cells of Murine Lung

Published on: November 16, 2021

6.5K

Area of Science:

  • Immunology
  • Oncology
  • Health Disparities

Background:

  • Racial and ethnic disparities in lung cancer presentation and outcomes are well-documented.
  • Understanding the underlying biological factors contributing to these disparities is crucial.

Purpose of the Study:

  • To investigate systemic immune parameter differences between Black and White patients with lung cancer.
  • To identify potential immune-related factors associated with observed racial disparities in lung cancer.

Main Methods:

  • Prospective collection of peripheral blood samples from Black and White lung cancer patients undergoing immunotherapy.
  • Analysis of cytokine levels using multiplex panels and immune cell populations via mass cytometry.
  • Statistical comparison of immune parameters between racial groups, with corrections for multiple comparisons.

Main Results:

  • Black patients (n=19) compared to White patients (n=168) with non-small cell lung cancer (NSCLC) had higher comorbidity and prior chemotherapy rates.
  • Significant differences in cytokine profiles were observed, with Black patients showing lower CCL23/CCL27 and higher CCL8/CXCL1/CCL26/CCL25/CCL1/IL-1b/CXCL16/IFN-γ levels.
  • Black patients exhibited increased populations of nonclassical CD16+ monocytes, NKT-like cells, CD4+ cells, CD38+ monocytes, and CD57+ gamma delta T cells.

Conclusions:

  • Black and White lung cancer patients display distinct systemic immune profiles.
  • Black patients demonstrate elevated levels of several pro-inflammatory cytokines and specific immune cell populations.
  • The etiological basis and clinical implications of these observed immune differences require further investigation.